An American-Irish manufacturer of pharmaceuticals. It was perviously part of an oligopoly of pharmaceutical companies that benefited from selling to the captive Palestinian market.
According to Who Profits, Perrigo has benefited from selling pharmaceuticals to the captive Palestinian market. In 2021, Perrigo announced that it had ended its business activities in Israel by selling its Generic Rx Pharmaceuticals business.
Because Israeli policies and regulations hinder the import of raw materials to occupied Palestine, place prohibitions and high costs on exports and deliveries to the occupied Palestinian territory, and exclude Arab markets, Perrigo was able to enjoy easy access to the Palestinian market. Free of customs charges, searches at military checkpoints, and other burdensome requirements enforced for Palestinian companies, Perrigo faced little to no competition.